Menu

Tag: Innovation in Manufacture Shortlist

Novartis Pharma

Shortlisted: Innovation in ManufactureRadio Ligand Therapy for Cancer Treatment Novartis successfully development formulation for clinical studies and commercial manufacturing of Pluvicto for treatment of Cancer patients. PluvictoTM (lutetium Lu 177 vipivotide tetraxetan) is indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have already been treated

Making Nutra

Making Pharma

Moving Pharma

20-21 April 2027

The NEC Birmingham

Organised by:

Step Exhibitions
Orchard House, North Farm Road
Tunbridge Wells, Kent
TN2 3XF United Kingdom

Step Exhibitions Ltd does not, under any circumstances make attendee data available
to third parties for resale.

Contact Us:

T: +44 (0) 1892 518877
E: makingpharma@step-exhibitions.com

Join the mailing list

View our Policies:

Privacy Policy
Admissions Policy

Making Nutra

Making Pharma

Moving Pharma

20-22 April 2027

The NEC Birmingham

Organised by:

Step Exhibitions
Orchard House, North Farm Road
Tunbridge Wells, Kent
TN2 3XF United Kingdom

Step Exhibitions Ltd does not, under any circumstances make attendee data available
to third parties for resale.

Contact Us:

T: +44 (0) 1892 518877
E: makingpharma@step-exhibitions.com

View our Policies:

Privacy Policy
Admissions Policy